Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.
Karen A. Gelmon
Honoraria - AstraZeneca; Eisai; Novartis; Roche
Maria Vidal
No relevant relationships to disclose
Marie-Paule Sablin
No relevant relationships to disclose
Rosanne Serpanchy
No relevant relationships to disclose
Jesus Soberino
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Diego Villa
No relevant relationships to disclose
Mustapha Zoubir
No relevant relationships to disclose
Ulrich Freudensprung
Employment or Leadership Position - Roche
Jian Xu
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Charlotte Colthorpe
Employment or Leadership Position - Roche
Veronique Dieras
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech